Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Skin Neoplasms 6Neoplasms 6Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Squamous Cell 4Neoplasm Metastasis 3Prostatic Neoplasms 2Lung Neoplasms 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Advanced Non-Small Cell Lung Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Resectable Non-small Cell Lung Cancer 1Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Motor Activity 1Liposarcoma 1Laryngeal Neoplasms 1Kidney Neoplasms 1

Interventions

durvalumab 18Bevacizumab 17atezolizumab 13lenvatinib 10Magnetic Resonance Spectroscopy 10tremelimumab 8Nivolumab 8pembrolizumab 7Sorafenib 6Specimen Handling 5camrelizumab 4cabozantinib 4Immunoglobulin G 4Disulfides 4sintilimab 3apatinib 3X-Rays 3Radiotherapy 3Radiofrequency Ablation 3Radiation 3Hepatectomy 3E-7386 3Doxorubicin 3Cyclophosphamide 3tislelizumab 2relatlimab 2dostarlimab 2budigalimab 2Standard of Care 2Simvastatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Hepatocellular × cemiplimab × Clear all
NCT03916627 2026-04-06

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
65 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡